Listed

Cypherpunk Technologies Inc.: Form 10-Q for the period ended Sep 30, 2023

Filed with the SEC on Nov 13, 2023 and accepted by EDGAR at Nov 13, 2023, 11:51 ET.

Share

Management's discussion and analysis

As filed, 26,657 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

The following Management’s Discussion and Analysis of Financial Condition and Results of Operations (“MD&A”) is intended to help the reader understand our results of operations and financial condition. This MD&A is provided as a supplement to, and should be read in conjunction with, our condensed consolidated financial statements and the accompanying notes thereto and other disclosures included in this Quarterly Report on Form 10-Q, including the disclosures under Part II, Item IA “Risk Factors,” and our audited condensed consolidated financial statements and the accompanying notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2022, which was filed with the Securities and Exchange Commission, or the SEC, on March 24, 2023. Our condensed consolidated financial statements have been prepared in accordance with U.S. GAAP and, unless otherwise indicated, amounts are presented in U.S. dollars.

Company Overview

We are a biopharmaceutical company developing biomarker-targeted antibody therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways, targeting cancer-specific cell surface molecules, and harnessing the immune system to attack cancer cells. Our strategy is to identify, acquire, and develop molecules that will rapidly translate into high impact therapeutics that generate durable clinical benefit and enhanced patient outcomes.

Our lead clinical stage program is DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, or DKK1. We are currently studying DKN-01 in multiple ongoing clinical trials in patients with esophagogastric cancer, gynecologic cancers, or colorectal cancer. Our second clinical stage program is FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface. We also have two preclinical antibody programs, FL-302 and FL-501.

We intend to apply our extensive experience identifying and developing transformational products to build a pipeline of programs that have the potential to change the practice of cancer medicine.

Recent Developments

Since June 30, 2023, we have continued to make progress with the development of DKN-01 and our business strategy.

DKN-01 Development Update

  • Updated data from Part A of the DeFianCe Study of DKN-01 plus bevacizumab and chemotherapy in colorectal cancer patients to be presented at a medical conference in early 2024. The Company expects to present new long-term follow-up data from Part A of the DeFiance study (NCT05480306), a Phase 2, randomized, open-label, multicenter study of DKN-01 in combination with standard of care bevacizumab and chemotherapy in patients with advanced colorectal cancer (CRC) who have received one prior systemic therapy for advanced disease. Initial results from Part A indicated an objective response rate (ORR) above 20% with a high disease control rate, which exceeded the benchmarks expected for this population. Subsequently, the study expanded into a 130-patient Part B randomized controlled trial.
  • Part C of the DisTinGuish Study of DKN-01 plus tislelizumab and chemotherapy in gastric cancer patients is ongoing. The DisTinGuish study (NCT0436380) is a Phase 2, randomized, open-label, multicenter study of DKN-01 in combination with tislelizumab and chemotherapy in first-line patients with advanced gastroesophageal adenocarcinoma (GEA). The Company previously presented long-term follow-up data from Part A of the study in June 2023, showing 73% ORR in the modified intent-to-treat (mITT) population, and 85% ORR in the PD-L1 low-subgroup. The data also demonstrated 19.5 months median overall survival and 11.3 months progression-free survival.

Financial Overview

Research and Development Expenses

Our research and development activities have included conducting nonclinical studies and clinical trials, manufacturing development efforts and activities related to regulatory filings for our product candidates, primarily DKN-01. We recognize research and development expenses as they are incurred. Our research and development expenses during the nine months ended September 30, 2023 consisted primarily of:

  • the fair value of the in-process research and development (“IPR&D”) acquired from Flame;
  • salaries and related overhead expenses for personnel in research and development functions, including costs related to stock-based compensation;
  • fees paid to consultants and CROs for our nonclinical and clinical trials, and other related clinical trial fees, including but not limited to laboratory work, clinical trial database management, clinical trial material management and statistical compilation and analysis;
  • costs related to acquiring and manufacturing clinical trial material; and
  • costs related to compliance with regulatory requirements.

We plan to increase our research and development expenses for the foreseeable future as we continue the development of DKN-01 and any other product candidates, subject to the availability of additional funding.

Our direct research and development expenses are tracked on a program-by-program basis and consist primarily of internal and external costs, such as employee costs, including salaries and stock-based compensation, other internal costs, fees paid to consultants, central laboratories, contractors and CROs in connection with our clinical and preclinical trial development activities. We use internal resources to manage our clinical and preclinical trial development activities and perform data analysis for such activities.

We participate, through our subsidiary in Australia, in the Australian government’s research and development (“R&D”) Incentive program (“R&D Incentive Program”), such that a percentage of our eligible research and development expenses are reimbursed by the Australian government as a refundable tax offset and such incentives are reflected as other income.

The table below summarizes our research and development expenses incurred by development program and the R&D Incentive income for the three and nine months ended September 30, 2023 and 2022:

(in thousands)

(in thousands)

​ ​ ​ ​ Direct research and development by program: ​ ​ ​ ​ ​ Three Months Ended September 30, 2023 ​ ​ ​ ​ 2022 ​ ​ ​ ​ ​ Nine Months Ended September 30, 2023 ​ ​ ​ ​ 2022 ​
DKN‑01 program ​ $11,016 ​ $12,080 ​ $31,153 ​ $33,843
TRX518 program ​ — ​ 22 ​ 22 ​ 88
FL-101 program ​ ​ 241 ​ ​ — ​ ​ 546 ​ ​ —
FL-301 program ​ ​ 137 ​ ​ — ​ ​ 137 ​ ​ —
FL-501 program ​ ​ 109 ​ ​ — ​ ​ 109 ​ ​ —
In-process research and development acquired from Flame ​ ​ — ​ ​ — ​ ​ 29,582 ​ ​ —
​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Total research and development expenses ​ $11,503 ​ $12,102 ​ $61,549 ​ $33,931
​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Australian research and development incentives ​ $554 ​ $652 ​ $1,124 ​ $1,276

The successful development of our clinical product candidates is highly uncertain. At this time, we cannot reasonably estimate the nature, timing or costs of the efforts that will be necessary to complete the remainder of the development of any of our product candidates or the period, if any, in which material net cash inflows from these product candidates may commence. This is due to the numerous risks and uncertainties associated with developing drugs, including the uncertainty of:

  • the scope, rate of progress and expense of our ongoing, as well as any additional, clinical trials and other research and development activities;
  • future clinical trial results; and
  • the timing and receipt of any regulatory approvals.

A change in the outcome of any of these variables with respect to the development of a product candidate could result in a significant change in the costs and timing associated with the development of that product candidate. For example, if the FDA or another regulatory authority were to require us to conduct clinical trials beyond those that we currently anticipate will be required for the completion of clinical development of a product candidate, or if we experience significant delays in enrollment in any of our clinical trials, we could be required to expend significant additional financial resources and time on the completion of clinical development.

General and Administrative Expenses

General and administrative expenses consist primarily of salaries and related costs, including stock-based compensation, for personnel in executive, finance and administrative functions. General and administrative expenses also include direct and allocated facility-related costs as well as professional fees for legal, patent, consulting, accounting and audit services.

We anticipate that our general and administrative expenses will increase in the future as we increase our headcount to support our continued research activities and development of our product candidates. We also anticipate that we will incur increased accounting, audit, legal, regulatory, compliance, director and officer insurance costs as well as investor and public relations expenses associated with being a public company.

Interest income

Interest income consists primarily of interest income earned on cash and cash equivalents.

Research and development incentive income

Research and development incentive income includes payments under the R&D Incentive Program from the government of Australia. The R&D Incentive Program is one of the key elements of the Australian government’s support for Australia’s innovation system. It was developed to assist businesses in recovering some of the costs of undertaking research and development. The research and development tax incentive provides a tax offset to eligible companies that engage in research and development activities.

Companies engaged in research and development may be eligible for either:

  • a refundable tax offset at a rate of 18.5% above the company’s tax rate for entities with income of less than A$20 million per annum; or
  • a non-refundable tax offset for all other entities which is a progressive marginal tiered R&D intensity threshold. Increasing rates of benefit apply for incremental research and development expenditure by intensity:
  • 0 to 2% intensity: an 8.5% premium to the company’s tax rate
  • Greater than 2% intensity: a 16.5% premium to the company’s tax rate;

We recognize as income the amount we expect to be reimbursed for qualified expenses.

Foreign currency translation adjustment

Foreign currency translation adjustment consists of gains (losses) due to the revaluation of foreign currency transactions attributable to changes in foreign currency exchange rates associated with our Australian subsidiary.

Critical Accounting Policies and Estimates

Our condensed consolidated financial statements are prepared in accordance with GAAP. The preparation of our financial statements and related disclosures requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenue, costs and expenses, and the disclosure of contingent assets and liabilities in our financial statements. We base our estimates on historical experience, known trends and events and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions or conditions.

Our critical accounting policies are described under the heading “Management’s Discussion and Analysis of Financial Condition and Results of Operations— Critical Accounting Policies and Significant Judgments and Estimates” in our Annual Report on Form 10-K filed with the SEC on March 24, 2023, and the notes to the condensed consolidated financial statements appearing elsewhere in this Quarterly Report on Form 10-Q. We believe that of our critical accounting policies, the following accounting policies involve the most judgment and complexity:

  • accrued research and development expenses;
  • research and development incentive receivable; and
  • stock-based compensation.

Results of Operations

Comparison of the Three Months Ended September 30, 2023 and 2022

The following table summarizes our results of operations for the three months ended September 30, 2023 and 2022:

(in thousands)

​ ​ ​ ​ Operating expenses: ​ ​ ​ ​ ​ ​ Three Months Ended September 30, 2023 ​ ​ ​ ​ ​ 2022 ​ ​ ​ ​ ​ ​ ​ ​ Change ​ ​
Research and development ​ $11,503 ​ $12,102 ​ $(599)
General and administrative ​ 3,330 ​ 3,186 ​ 144
Total operating expenses ​ 14,833 ​ 15,288 ​ (455)
Loss from operations ​ (14,833) ​ (15,288) ​ 455
Interest income ​ 1,084 ​ 360 ​ 724
Interest expense ​ — ​ (11) ​ 11
Australian research and development incentives ​ 554 ​ 652 ​ (98)
Foreign currency loss ​ (501) ​ (807) ​ 306
Net loss ​ $(13,696) ​ $(15,094) ​ $1,398

Research and Development Expenses

(in thousands)

​ ​ ​ ​ ​ Direct research and development by program: ​ ​ ​ ​ ​ Three Months Ended September 30, ​ ​ 2023 ​ ​ ​ ​ ​ ​ ​ 2022 ​ ​ ​ ​ ​ ​ ​ ​ ​ Increase (Decrease) ​ ​ ​
DKN‑01 program ​ $11,016 ​ $12,080 ​ $(1,064)
TRX518 program ​ — ​ 22 ​ (22)
FL-101 program ​ ​ 241 ​ ​ — ​ ​ 241
FL-301 program ​ ​ 137 ​ ​ — ​ ​ 137
FL-501 program ​ ​ 109 ​ ​ — ​ ​ 109
​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Total research and development expenses ​ $11,503 ​ $12,102 ​ $(599)

Research and development expenses were $11.5 million for the three months ended September 30, 2023, compared to $12.1 million for the three months ended September 30, 2022. The decrease of $0.6 million in R&D expenses during the three months ended September 30, 2023 as compared to the same period in 2022, was due to a decrease of $2.5 million in manufacturing costs related to clinical trial material and manufacturing campaigns. This decrease was partially offset by an increase of $1.1 million in clinical trial costs and an increase of $0.8 million in payroll and other related expenses due to an increase in headcount of our R&D full-time employees.

General and Administrative Expenses

General and administrative expenses were $3.3 million for the three months ended September 30, 2023, compared to $3.2 million for the three months ended September 30, 2022. The increase of $0.1 million in general and administrative expenses was due to an increase of $0.1 million increase in payroll and other related expenses due to an increase in headcount of our general and administrative full-time employees.

Interest Income

During the three months ended September 30, 2023, we recorded interest income of $1.1 million. During the three months ended September 30, 2022, we recorded interest income of $0.4 million. The increase during the three months ended September 30, 2023 as compared to the same period in 2022 was due to higher interest rates earned on interest bearing cash accounts.

Australian Research and Development Incentives

We recorded R&D incentive income of $0.6 million and $0.7 million during the three months ended September 30, 2023 and 2022, respectively, based upon the applicable percentage of eligible research and development activities under the R&D Incentive Program, which expenses included the cost of manufacturing clinical trial material.

The R&D incentive receivable has been recorded as “Research and development incentive receivable” in the condensed consolidated balance sheets.

Foreign Currency Gains (loss)

During the three months ended September 30, 2023 and 2022, we recorded foreign currency transaction losses of $0.5 million and $0.8 million, respectively. Foreign currency transaction gains and losses are due to changes in the Australian dollar exchange rate related to activities of the Australian entity.

Comparison of the Nine Months Ended September 30, 2023 and 2022

The following table summarizes our results of operations for the nine months ended September 30, 2023 and 2022:

(in thousands)

​ ​ ​ ​ Operating expenses: ​ ​ ​ ​ ​ Nine Months Ended September 30, 2023 ​ ​ ​ ​ 2022 ​ ​ ​ ​ ​ ​ Change ​ ​ ​
Research and development ​ $61,549 ​ $33,931 ​ $27,618
General and administrative ​ 10,672 ​ 8,889 ​ 1,783
Total operating expenses ​ 72,221 ​ 42,820 ​ 29,401
Loss from operations ​ (72,221) ​ (42,820) ​ (29,401)
Interest income ​ 3,089 ​ 404 ​ 2,685
Interest expense ​ — ​ (49) ​ 49
Australian research and development incentives ​ 1,124 ​ 1,276 ​ (152)
Foreign currency loss ​ (953) ​ (1,305) ​ 352
Change in fair value of Series X preferred stock warrant liability ​ 12 ​ — ​ 12
Net loss ​ $(68,949) ​ $(42,494) ​ $(26,455)

Research and Development Expenses

(in thousands)

​ ​ ​ ​ ​ Direct research and development by program: ​ ​ ​ ​ ​ ​ ​ Nine Months Ended September 30, ​ ​ 2023 ​ ​ ​ ​ ​ ​ ​ ​ 2022 ​ ​ ​ ​ ​ ​ ​ ​ ​ Increase (Decrease) ​ ​ ​
DKN-01 program ​ $31,153 ​ $33,843 ​ $(2,690)
TRX518 program ​ 22 ​ 88 ​ (66)
FL-101 program ​ 546 ​ — ​ 546
FL-301 program ​ ​ 137 ​ ​ — ​ ​ 137
FL-501 program ​ ​ 109 ​ ​ — ​ ​ 109
In-process research and development acquired from Flame ​ 29,582 ​ — ​ 29,582
​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Total research and development expenses ​ $61,549 ​ $33,931 ​ $27,618

Research and development expenses were $61.5 million for the nine months ended September 30, 2023, compared to $33.9 million for the nine months ended September 30, 2022. The increase of $27.6 million in R&D expenses during the nine months ended September 30, 2023 as compared to the same period in 2022, was primarily due to $29.6 million of in-process research and development (“IPR&D”) acquired in the Flame merger which the Company expensed during the nine months ended September 30, 2023. There was also an increase of $2.3 million in payroll and other related expenses due to an increase in headcount of our R&D full-time employees, an increase of $1.8 million in clinical trial costs and an increase of $0.3 million in stock-based compensation expense due to new stock options granted to R&D full-time employees. These increases were partially offset by a $6.4 million decrease in manufacturing costs related to clinical trial material and manufacturing campaigns.

General and Administrative Expenses

General and administrative expenses were $10.7 million for the nine months ended September 30, 2023, compared to $8.9 million for the nine months ended September 30, 2022. The increase of $1.8 million in general and administrative expenses was primarily due to an increase of $1.6 million in professional fees due to higher finance and legal costs associated with our business development activities and a $0.6 million increase in payroll and other related expenses due to an increase in headcount of our general and administrative full-time employees. These increases were partially offset by a decrease of $0.4 million in insurance costs.

Interest Income

During the nine months ended September 30, 2023, we recorded interest income of $3.1 million. During the nine months ended September 30, 2022, we recorded interest income of $0.4 million. The increase during the nine months ended September 30, 2023 as compared to the same period in 2022 was due to higher interest rates earned on interest bearing cash accounts.

Australian Research and Development Incentives

We recorded R&D incentive income of $1.1 million and $1.3 million during the nine months ended September 30, 2023 and 2022, respectively, based upon the applicable percentage of eligible research and development activities under the R&D Incentive Program, which expenses included the cost of manufacturing clinical trial material.

The R&D incentive receivable has been recorded as “Research and development incentive receivable” in the condensed consolidated balance sheets.

Foreign Currency Gains (loss)

During the nine months ended September 30, 2023 and 2022, we recorded foreign currency transaction losses of $1.0 million and $1.3 million, respectively. Foreign currency transaction gains and losses are due to changes in the Australian dollar exchange rate related to activities of the Australian entity.

Financial Position, Liquidity and Capital Resources

Since our inception, we have been engaged in organizational activities, including raising capital, and research and development activities. We do not yet have a product that has been approved by the Food and Drug Administration (the “FDA”), have not yet achieved profitable operations, nor have we ever generated positive cash flows from operations. There is no assurance that profitable operations, if achieved, could be sustained on a continuing basis. Further, our future operations are dependent on the success of efforts to raise additional capital, our research and commercialization efforts, regulatory approval, and, ultimately, the market acceptance of our products.

In accordance with Accounting Standards Codification (“ASC”) 205-40, Going Concern, we have evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about our ability to continue as a going concern within one year after the date that the condensed consolidated financial statements are issued. As of September 30, 2023, we had cash and cash equivalents of $80.7 million. Additionally, we had an accumulated deficit of $387.1 million at September 30, 2023, and during the nine months ended September 30, 2023, we incurred a net loss of $68.9 million. We expect to continue to generate operating losses in the foreseeable future. We believe that our cash and cash equivalents of $80.7 million as of September 30, 2023 will be sufficient to fund our operating expenses for at least the next 12 months from the issuance of this report on Form 10-Q.

In addition, to support our future operations, we will seek additional funding through public or private equity financings or government programs and will seek funding or development program cost-sharing through collaboration agreements or licenses with larger pharmaceutical or biotechnology companies. If we do not obtain additional funding or development program cost-sharing, we could be forced to delay, reduce or eliminate certain clinical trials or research and development programs, reduce or eliminate discretionary operating expenses, and delay company and pipeline expansion, which could adversely affect our business prospects. The inability to obtain funding, as and when needed, could have a negative impact on Leap’s financial condition and our ability to pursue our business strategies.

Cash Flows

The following table summarizes our sources and uses of cash for each of the periods presented:

(in thousands)

​ ​ ​ ​ ​ ​ ​ ​ ​ Nine Months Ended September 30, 2023 ​ ​ ​ 2022
Cash used in operating activities ​ $(33,373) ​ $(36,030)
Cash provided by investing activities ​ ​ 48,969 ​ ​ —
Cash used in financing activities ​ (30) ​ (210)
Effect of exchange rate changes on cash and cash equivalents ​ (323) ​ (368)
Net increase (decrease) in cash and cash equivalents ​ $15,243 ​ $(36,608)

Operating activities. Net cash used in operating activities for the nine months ended September 30, 2023 was primarily related to our net loss from the operation of our business of $68.9 million and net changes in working capital, including a decrease in accounts payable and accrued expenses of $1.0 million and a decrease in lease liabilities of $0.3 million. These changes were partially offset by a decrease in research and development incentive receivable of $1.3 million, a decrease of $0.8 million in other assets, a decrease of $0.1 million in prepaid expenses and other assets, noncash IPR&D expense of $29.6 million, noncash stock based compensation expense of $3.9 million, foreign currency transaction losses of $1.0 million and change in a right-of-use asset of $0.3 million.

Net cash used in operating activities for the nine months ended September 30, 2022 was primarily related to our net loss from the operation of our business of $42.5 million and net changes in working capital, including an increase in other long term assets of $0.9 million, a decrease in lease liability of $0.3 million and an increase in research and development receivable of $0.2 million. These changes were partially offset by an increase in accounts payable and accrued expenses of $2.2 million and a decrease of $0.4 million in prepaid expenses. During the nine months ended September 30, 2022, there was also noncash stock based compensation expense of $3.7 million, foreign currency losses of $1.3 million and a change in right-of-use asset of $0.3 million.

Investing Activities. Net cash provided by investing activities for the nine months ended September 30, 2023 was related to cash acquired in connection with the acquisition of Flame of $50.4 million and payment of direct and incremental costs of $1.4 million associated with the acquisition of Flame. There were no investing activities during the nine months ended September 30, 2022.

Financing Activities. Net cash used in financing activities for the nine months ended September 30, 2023 primarily consisted of an immaterial amount paid by the Company for the redemption of 10,000 shares of the 2019 warrants. Net cash used in financing activities for the nine months ended September 30, 2022 consisted of payments of deferred offering costs of $0.2 million.

Controls and procedures

As filed, 2,493 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Evaluation of Disclosure Controls and Procedures

We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in the reports that we file or submit under the Securities Exchange Act of 1934, as amended (the “Exchange Act”) is (1) recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms and (2) accumulated and communicated to our management, including our President and Chief Executive Officer, who is also serving as Chief Financial Officer and therefore currently serves as both our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure.

As of September 30, 2023, our management, with the participation of our Chief Executive Officer, who is also serving as Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) using the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control—Integrated Framework (2013 Framework). Our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives, and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Our principal executive officer and principal financial officer has concluded, based upon the evaluation described above, that, as of September 30, 2023, our disclosure controls and procedures were effective to ensure that information required to be disclosed by us in reports the Company files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC, and that such material information is accumulated and communicated to the Company’s management, including its principal executive officer and principal financial officer, to allow timely decisions regarding required disclosure.

Changes in Internal Control over Financial Reporting

During the three months ended September 30, 2023, there were no changes in our internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act) that materially affected, or are reasonably likely to affect, internal control over financial reporting.

Risk factors

As filed, 515 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

An investment in our ordinary shares involves a high degree of risk. You should carefully consider the risk factors discussed in Part I, Item 1A “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2022 as filed with the SEC on March 24, 2023, along with those discussed in our definitive proxy statement filed on April 28, 2023 and our Quarterly Report on Form 10-Q filed on May 15, 2023, which could materially affect our business, financial condition, operating results or cash flows.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2023-09-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Research and development3 months2023-07-01 to 2023-09-30$11.5mus-gaap:ResearchAndDevelopmentExpense
Research and development9 months2023-01-01 to 2023-09-30$61.5mus-gaap:ResearchAndDevelopmentExpense
Operating income3 months2023-07-01 to 2023-09-30−$14.8mus-gaap:OperatingIncomeLoss
Operating income9 months2023-01-01 to 2023-09-30−$72.2mus-gaap:OperatingIncomeLoss
Net income3 months2023-07-01 to 2023-09-30−$13.7mus-gaap:NetIncomeLoss
Net income9 months2023-01-01 to 2023-09-30−$68.9mus-gaap:NetIncomeLoss
Diluted EPS3 months2023-07-01 to 2023-09-30−$0.51us-gaap:EarningsPerShareDiluted
Diluted EPS9 months2023-01-01 to 2023-09-30−$3.78us-gaap:EarningsPerShareDiluted
Basic EPS3 months2023-07-01 to 2023-09-30−$0.51us-gaap:EarningsPerShareBasic
Basic EPS9 months2023-01-01 to 2023-09-30−$3.78us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2023-07-01 to 2023-09-3026,987,182 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Diluted shares (weighted)9 months2023-01-01 to 2023-09-3018,240,455 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow9 months2023-01-01 to 2023-09-30−$33.4mus-gaap:NetCashProvidedByUsedInOperatingActivities
Cash and equivalentsAt period end2023-09-30$80.7mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2023-09-30$81.8mus-gaap:AssetsCurrent
Total assetsAt period end2023-09-30$83.0mus-gaap:Assets
Current liabilitiesAt period end2023-09-30$11.0mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2023-09-30$11.0mus-gaap:Liabilities
Shareholders' equityAt period end2023-09-30$72.0mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001410578-23-002343. Last ingested by Listed: Oct 24, 2026, 15:12 ET. Listed shows no prices and gives no investment advice.